PORTOLA VALLEY, Calif., Feb. 7, 2012 /PRNewswire/ --Spectros announced today that year-over-year sales revenue rose 69% in 2011. This is the fourth year in a row for double-digit revenue growth for Spectros since the current T-Stat Oximeter was launched in 2008.
"This accelerating growth continues to send a strong signal that the market is embracing the Spectros broadband tissue oximetry," notes CFO John Bagnatori.
Spectros T-Stat® is the only broadband tissue oximeter on the market in the U.S., Europe, and Asia. T-Stat's proprietary broadband oximetry relies on over 260 wavelengths of light, compared just 2-4 wavelengths used in other oximeters. T-Stat competes with INVOS® oximeters marketed by Covidien, and FORE-SIGHT® oximeters marketed by CAS Medical. In reconstructive surgery, T-Stat competes with oximeters marketed by ViOptix.
An expanded array of products, including broadband infrared Ceres cerebral probes and multi-site T-Stat monitors are under development.
Spectros markets advanced molecular devices that shed light on ischemia and cancer. Spectros is also developing molecular imaging contrast agents for surgical guidance during breast and prostate cancer surgeries, currently undergoing phase I/II clinical trials. Spectros is a venture-supported concern.
(Note: Forward-looking statements do not constitute an offer for investment nor a guarantee of future events or returns. Certain applications described above have not been reviewed by the FDA, and are therefore labeled for investigational use only. T-Stat is a trademark of Spectros. INVOS is a trademark of Somanetics and Covidien). FORE-SIGHT is a trademark of CAS Medical.
For further information, visit www.spectros.com.
Web Site: http://www.spectros.com